Channel - Radiobiology
6/21/2022 12:56:42 AM

Channel Videos

A Radiobiology Markov Simulation Tool for Aiding Decision Making in Proton Therapy Referral
Scott Penfold
10/30/2015 10:00:00 PM

Breast cancer radiobiology - a new perspective and clinical application
Associate Professor John Yarnold
10/4/2007 2:30:00 PM

Collagen and hypoxia-related gene expression associated with CT texture parameters in non-small cell lung cancer
Aileen Cormican
9/4/2014 4:00:00 AM

Contouring Variability and its Effect on Radiobiology
Michael Geoffrey Jameson
10/24/2009 6:18:00 AM

Effects of synchrotron microbeam radiotherapy on tumour-associated neutrophil and macrophage recruitment in a mouse breast cancer model
Yuqing Yang
9/4/2014 3:45:00 AM

FROGG #8 Genitourinary Sessions for Radiation Oncology supported by Mundipharma
Topic: Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach Renal cell carcinoma (RCC) is the 8th most common cancer in Australia. When localised it is managed predominantly with surgery and less frequently with interventional thermal ablation techniques. RCC is considered traditionally radioresistant and radiotherapy has limited utility outside of occasional palliation in advanced disease. With the advent of newer techniques such as stereotactic ablative body radiotherapy (SABR), radiotherapy is enjoying a renaissance in its uptake in the management of RCC. In order to keep up-to-date with advances in knowledge in the role of radiotherapy for primary RCC, this lecture will explore several fundamental concepts. This includes the radiobiology of RCC, technical aspects of SABR delivery in primary RCC, use of SABR in for larger renal masses, outcomes of SABR with solitary kidneys, renal function and nephron sparing approaches with SABR, and the use of SABR as a cytoreductive therapy to the primary in advanced RCC. Learning objectives - Radiobiology of radio resistance in renal cell carcinoma - Indications for SABR in primary RCC and expected outcomes - Technical considerations for SABR in primary RCC - Outcomes expected for SABR in metastatic RCC - SABR in the context of systemic therapies Meet our guest speaker: Associate Professor Shankar Siva (PhD) is a radiation oncologist and leads the stereotactic body radiotherapy (SABR) service at the Peter MacCallum Cancer Centre. He has over 200 manuscript publications, including original works in leading journals such as Lancet Onc, JAMA Onc, European Urology and Journal of Thoracic Oncology. He leads 5 international multicentre trials through the TransTasman Radiation Oncology Group (TROG) with a focus in SABR. His current research program focuses on high-tech radiotherapy delivery, in the context of SABR and immunotherapy combinations, oligometastatic disease, lung, kidney cancer and prostate cancer.
Default Presenter
5/19/2022 9:00:00 AM

Monte-Carlo model development for evaluation of current clinical target volume (CTV) definition for glioblastoma (GBM)
Leyla Moghaddasi
9/4/2014 4:30:00 AM

Prostate Hypofractionation - Radiobiology in Action
Presentation delivered at the RANZCR ASM 2018
A/Prof Jared Martin
10/26/2018 11:30:00 PM

RAD21 cohesin overexpression is a prognostic and predictive prognosis in KRAS mutant colorectal carcinomas
Reza Masoud Rahbari
9/4/2014 4:15:00 AM

Radiation dose enhancement by Bi2S3 nanoparticles; Cell culture studies
Moshi Geso
9/4/2014 4:45:00 AM

The effect of increasing radiation doses on normal & malignant cell migration
Jeffrey Crosbie
9/4/2014 3:30:00 AM

Mediasite Showcase
Mediasite's the trusted cornerstone of any campus or enterprise video strategy. Our unyielding commitment to all things video helps you transform education, training, communications and online events.
Webcasting Video Content Management Video Delivery Integration Services Mediasite Community
Powered By Mediasite - Enterprise Video Platform
Sonic Foundry